EPO and chronic kidney disease: sHPT is a consequence and key mediator of CKD mineral bone disorder (CKD-MBD) and linked to disturbed calcium (Ca) and phosphate homeostasis, renal osteodystrophy, vascular and valvular calcification, erythropoietin hypo-responsiveness, and cardiovascular morbidity and mortality (1–3).